Immunomedics

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

Gilead Sciences

Initial partnership discussions between Gilead Sciences Inc and biopharmaceutical company Immunomedics Inc have shifted to acquisition, which would mean an expansion of Gilead’s portfolio of cancer treatments.

Gilead is getting closer to a deal to buy Immunomedics for more than $20 billion

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Gilead nears deal to buy Immunomedics for more than $20 billion - WSJ

Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy ™  in brain tumors  

Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock?

Why Is Immunomedics (IMMU) Down 6.7% Since Last Earnings Report?

MORRIS PLAINS, N.J., Sept.  02, 2020  (GLOBE NEWSWIRE) --  Immunomedics, Inc.  (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences:

Immunomedics to Participate in Upcoming Healthcare Conferences

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Immunomedics Inc.

(IMMU) Alert: Shareholder Class Action Against Immunomedics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

Bristol-Myers

Cigna

Medtronic

With earnings reporting for the second quarter all but over, and the summer starting to wind down, many of the top companies we follow on Wall Street are making some changes to the lists of their high-conviction stock picks for clients.

BofA Securities Adds Medical Technology Giant to the US 1 List

Esperion Therapeutics

Sales of these recently launched products could make a big difference for the companies behind them.

3 New Drug Launches of 2020 -- and the Stocks That Could Win Big

Immunomedics, Inc. (IMMU) Management on Q2 2020 Results - Earnings Call Transcript

Immunomedics (IMMU) delivered earnings and revenue surprises of 11.76% and -19.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Immunomedics (IMMU) Reports Q2 Loss, Lags Revenue Estimates

Encouraging early adoption of Trodelvy ™  in U.S. with $20.1M net sales in first two months of launch

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update

Immunomedics, Inc. (NASDAQ: IMMU) stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst.

Immunomedics Analyst Says Trodelvy Likely To Capture 50% Market Share

MORRIS PLAINS, N.J., July  27, 2020  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2020 and provide a corporate update.

Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020

Co-Diagnostics

GenMark Diagnostics

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD

Roche Holding AG

Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.

Immunomedics Extends Deal With Roche for Two New Studies

Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer

Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers

The company has a strong pipeline of antibody-drug conjugates

Immunomedics: A Solid Cancer Research Play

Is  (IMMU) Outperforming Other Medical Stocks This Year?

Is Immunomedics (IMMU) Outperforming Other Medical Stocks This Year?

Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.

Immunomedics' Shares Rise on Positive Breast Cancer Drug Data

Shares of Immunomedics Inc. IMMU, +7.31% gained 6.9% in trading on Monday after the drugmaker said a confirmatory Phase 3 clinical trial of its breast-cancer drug Trodelvy met its primary and secondary endpoints.

Shares of Immunomedics jump on positive confirmatory data for its breast-cancer drug

Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.

Immunomedics' Shares Surge YTD on Cancer Drug Approval

Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC

Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

SAN DIEGO & MORRIS PLAINS, N.J.--(BUSINESS WIRE)---- $IMMU #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. (NASDAQ: IMMU) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is deve

Shareholder Alert: Robbins LLP Announces It Is Investigating Immunomedics, Inc. (IMMU) for Misleading Shareholders

SAN DIEGO & MORRIS PLAINS, N.J.--(BUSINESS WIRE)---- $IMMU #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that purchasers of Immunomedics, Inc. (NASDAQ: IMMU) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between April 20, 2016 and June 2, 2016. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is developi

News for Immunomedics Stock (IMMU)